Ausdal Financial Partners’s Oncolytics Biotech ONCY Stock Holding History

Ausdal Financial Partners’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4K	Hold	12,000	–	–	﹤0.01%	1041
2026 Q1	$10.2K	Hold	12,000	–	–	﹤0.01%	983
2025 Q4	$10.5K	Hold	12,000	–	–	﹤0.01%	940
2025 Q3	$16.8K	Hold	12,000	–	–	﹤0.01%	931
2025 Q2	$9.28K	Sell	12,000 -2,400	-17%	-$1.27K	﹤0.01%	688
2025 Q1	$7.92K	Sell	14,400 -600	-4%	-$439	﹤0.01%	641
2024 Q4	$13.7K	Buy	15,000 +1,000	+7%	+$1.04K	﹤0.01%	566
2024 Q3	$12.2K	Sell	14,000 -7,000	-33%	-$6.87K	﹤0.01%	517
2024 Q2	$20.8K	Sell	21,000 -5,000	-19%	-$5.45K	﹤0.01%	493
2024 Q1	$27.6K	Sell	26,000 -4,000	-13%	-$4.47K	﹤0.01%	464
2023 Q4	$40.5K	Buy	30,000 +10,000	+50%	+$15.6K	0.01%	450
2023 Q3	$43.6K	Buy	+20,000	New	+$48.9K	0.01%	424

Other funds holding ONCY

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Ausdal Financial Partners's ONCY Position: Q2 2026 in Review

Ausdal Financial Partners held its Oncolytics Biotech (ONCY) position steady in Q2 2026 at 12,000 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1041.

Ausdal Financial Partners first reported a position in ONCY in Q3 2023 and has held it in 12 quarters since. The position peaked at $43.6K in Q3 2023. 75 funds tracked by Wall St. Rank hold ONCY as of Q2 2026.

Ausdal Financial Partners held 12,000 shares of Oncolytics Biotech worth $11.4K as of Q2 2026.
Ausdal Financial Partners left its Oncolytics Biotech share count unchanged in Q2 2026.
Oncolytics Biotech made up ﹤0.01% of Ausdal Financial Partners's portfolio in Q2 2026, its #1041 holding.
Ausdal Financial Partners first reported a position in Oncolytics Biotech in Q3 2023 and has held it in 12 quarters since.
Ausdal Financial Partners's Oncolytics Biotech position peaked at $43.6K in Q3 2023.
75 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q2 2026.

Based on Ausdal Financial Partners's 13F filing for Q2 2026, filed 14 Aug 2026.